Threlkeld A B, Shields M B
Joseph M. Bryan Glaucoma Clinic, Duke University Eye Center, Durham, North Carolina, USA.
Am J Ophthalmol. 1995 Nov;120(5):569-76. doi: 10.1016/s0002-9394(14)72203-2.
To evaluate the effect of noncontact transscleral Nd:YAG cyclophotocoagulation for refractory glaucoma after penetrating keratoplasty on intraocular pressure, visual acuity, and graft status.
We reviewed the records of all patients treated at the Duke University Eye Center between 1988 and 1993 who had noncontact transscleral Nd:YAG cyclophotocoagulation for uncontrolled glaucoma associated with penetrating keratoplasty.
One eye each of 39 patients was included in the study. At final follow-up, ranging from three to 63 months (mean, 27 +/- 18 months), the average decrease in intraocular pressure was 15 mm Hg (P = .001). Thirty-one patients (77%) had a final intraocular pressure between 7 and 21 mm Hg. The number of medications was reduced by an average of 1.4 (P = .0001). Five patients (13%) showed an improvement in best-corrected visual acuity at final follow-up; 12 (31%) maintained stable acuity, and 22 (56%) demonstrated a- deterioration in acuity. Of 25 patients with clear grafts before cyclophotocoagulation, 11 (44%) had graft decompensation.
Noncontact transscleral Nd:YAG cyclophotocoagulation is effective in lowering intraocular pressure in eyes with refractory glaucoma and associated penetrating keratoplasty, although loss of visual acuity and graft decompensation remain important concerns. Further study is needed of other cyclophotocoagulation protocols and alternative treatments for this patient population.
评估穿透性角膜移植术后难治性青光眼行非接触式经巩膜Nd:YAG睫状体光凝术对眼压、视力及植片状态的影响。
我们回顾了1988年至1993年间在杜克大学眼科中心接受治疗的所有患者的记录,这些患者因穿透性角膜移植术后青光眼控制不佳而行非接触式经巩膜Nd:YAG睫状体光凝术。
39例患者各1只眼纳入研究。末次随访时间为3至63个月(平均27±18个月),眼压平均下降15 mmHg(P = .001)。31例患者(77%)末次眼压在7至21 mmHg之间。药物数量平均减少1.4种(P = .0001)。5例患者(13%)在末次随访时最佳矫正视力有所提高;12例(31%)视力保持稳定,22例(56%)视力下降。在睫状体光凝术前25例植片透明的患者中,11例(44%)发生了植片失代偿。
非接触式经巩膜Nd:YAG睫状体光凝术在降低穿透性角膜移植术后难治性青光眼患者的眼压方面是有效的,尽管视力丧失和植片失代偿仍是重要问题。对于该患者群体,需要进一步研究其他睫状体光凝方案和替代治疗方法。